Are Non-Steroidal Anti-Inflammatory Drugs Effective for the Management
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
United States Patent (19) 11 Patent Number: 5,955,504 Wechter Et Al
USOO5955504A United States Patent (19) 11 Patent Number: 5,955,504 Wechter et al. (45) Date of Patent: Sep. 21, 1999 54 COLORECTAL CHEMOPROTECTIVE Marnett, “Aspirin and the Potential Role of Prostaglandins COMPOSITION AND METHOD OF in Colon Cancer, Cancer Research, 1992; 52:5575–89. PREVENTING COLORECTAL CANCER Welberg et al., “Proliferation Rate of Colonic Mucosa in Normal Subjects and Patients with Colonic Neoplasms: A 75 Inventors: William J. Wechter; John D. Refined Immunohistochemical Method.” J. Clin Pathol, McCracken, both of Redlands, Calif. 1990; 43:453-456. Thun et al., “Aspirin Use and Reduced Risk of Fatal Colon 73 Assignee: Loma Linda University Medical Cancer." N Engl J Med 1991; 325:1593-6. Center, Loma Linda, Calif. Peleg, et al., “Aspirin and Nonsteroidal Anti-inflammatory Drug Use and the Risk of Subsequent Colorectal Cancer.” 21 Appl. No.: 08/402,797 Arch Intern Med. 1994, 154:394–399. 22 Filed: Mar 13, 1995 Gridley, et al., “Incidence of Cancer among Patients With Rheumatoid Arthritis J. Natl Cancer Inst 1993 85:307-311. 51) Int. Cl. .......................... A61K 31/19; A61K 31/40; Labayle, et al., “Sulindac Causes Regression Of Rectal A61K 31/42 Polyps. In Familial Adenomatous Polyposis” Gastroenterol 52 U.S. Cl. .......................... 514/568; 514/569; 514/428; ogy 1991 101:635-639. 514/416; 514/375 Rigau, et al., “Effects Of Long-Term Sulindac Therapy On 58 Field of Search ..................................... 514/568, 570, Colonic Polyposis” Annals of Internal Medicine 1991 514/569, 428, 416, 375 11.5:952-954. Giardiello.et al., “Treatment Of Colonic and Rectal 56) References Cited Adenomas With Sulindac In Familial Adenomatous Poly U.S. -
Universitätsspital Balgrist, Zürich Chiropraktische Medizin Kommissarischer Leiter: Prof
Universitätsspital Balgrist, Zürich Chiropraktische Medizin Kommissarischer Leiter: Prof. Dr. Armin Curt, MD, FRCPC Betreuung der Masterarbeit: Dr. Brigitte Wirth, PT, PhD Leitung der Masterarbeit: Prof. em. Dr. Barry Kim Humphreys, BSc, DC, PhD A SYSTEMATIC REVIEW ON QUANTIFIABLE PHYSICAL RISK FACTORS FOR NON-SPECIFIC ADOLESCENT LOW BACK PAIN MASTERARBEIT zur Erlangung des akademischen Grades Master in Chiropraktischer Medizin (M Chiro Med) der Medizinischen Fakultät der Universität Zürich vorgelegt von Tobias Potthoff (09-712-712) 2017 Table of Content 1. Scientific Accompanying Text .......................................................................................................... 3 2. Abstract ......................................................................................................................................... 13 3. Introduction ................................................................................................................................... 14 4. Methods ........................................................................................................................................ 15 a. Search strategy .......................................................................................................................... 15 b. Inclusion criteria ........................................................................................................................ 15 c. Study selection ......................................................................................................................... -
Solid Solution Compositions and Use in Chronic Inflammation
(19) *EP003578172A1* (11) EP 3 578 172 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 11.12.2019 Bulletin 2019/50 A61K 9/14 (2006.01) A61K 47/14 (2017.01) A61K 47/44 (2017.01) A61K 31/12 (2006.01) (2006.01) (2006.01) (21) Application number: 19188174.7 A61K 31/137 A61K 31/167 A61K 31/192 (2006.01) A61K 31/216 (2006.01) (2006.01) (2006.01) (22) Date of filing: 14.01.2014 A61K 31/357 A61K 31/366 A61K 31/4178 (2006.01) A61K 31/4184 (2006.01) A61K 31/522 (2006.01) A61K 31/616 (2006.01) A61K 31/196 (2006.01) (84) Designated Contracting States: • BREW, John AL AT BE BG CH CY CZ DE DK EE ES FI FR GB London, Greater London EC2Y 8AD (GB) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • REILEY, Richard Robert PL PT RO RS SE SI SK SM TR London, Greater London EC2Y 8AD (GB) • CAPARRÓS-WANDERLEY, Wilson (30) Priority: 14.01.2013 US 201361752356 P London, Greater London EC2Y 8AD (GB) 04.02.2013 US 201361752309 P (74) Representative: Clements, Andrew Russell Niel et (62) Document number(s) of the earlier application(s) in al accordance with Art. 76 EPC: Schlich 14702460.8 / 2 925 367 9 St Catherine’s Road Littlehampton, West Sussex BN17 5HS (GB) (71) Applicant: InFirst Healthcare Limited London EC2Y 8AD (GB) Remarks: This application was filed on 24-07-2019 as a (72) Inventors: divisional application to the application mentioned • BANNISTER, Robin Mark under INID code 62. -
Injuries and Affections of the Spine ศ.นพ.พิบูลย์ อิทธิระวิวงศ์ ภาควิชาออร์โธปิดิกส์ I
Injuries and Affections of the Spine ศ.นพ.พิบูลย์ อิทธิระวิวงศ์ ภาควิชาออร์โธปิดิกส์ I. Injuries of the spine and thorax :- Classification 1. Major fractures and displacements of the cervical spine - Wedge compression fracture of vertebral body - Burst fracture of vertebral body - Extension subluxation - Flexion subluxation - Dislocation and fracture-dislocation - Fracture of the aieas - Fracture-dislocation of atlanto-axial joint - Intra-spinal displacements of soft tissue 2. Major fractures and displacements of the thoracic and lumbar vertebrae - Wedge compression fracture of vertebral body - Burst fracture of vertebral body - Dislocation and fracture-dislocation 3. Paraplegia from spinal injuries 4. Minor fractures of the spinal column - Fracture of transverse processes - Fracture of spinous processes - Fracture of the sacrum - Fracture of the coccyx 5. Fractures of the thoracic case - Fracture of the ribs - Fracture of the sternum II. Orthopaedic disorders of the spine Disorders Neck and cervical spine Trunk and spine (T,L,S) Congenital - Lumbar and sacral variations, abnormalities Hemivertebra. Spina bifida. Deformities Infantile torticollis Scoliosis. Congenital short neck Kyphosis. Congenital high spcapula Lordosis. Infections of bone Tuberculosis of C-spine Tuberculosis of T or L-spine Pyogenic infection of C- Pyogenic infection of T of L-spine. spine Arthritis of the spinal Ankylosing spondylitis Rheumatoid arthritis Osteoarthritis joints Cervical spondylosis Ankylosing spondylitis Osteochondritis - Scheuermann’s disease Calve’s -
Evicore Spine Imaging Guidelines
CLINICAL GUIDELINES Spine Imaging Policy Version 1.0 Effective February 14, 2020 eviCore healthcare Clinical Decision Support Tool Diagnostic Strategies: This tool addresses common symptoms and symptom complexes. Imaging requests for individuals with atypical symptoms or clinical presentations that are not specifically addressed will require physician review. Consultation with the referring physician, specialist and/or individual’s Primary Care Physician (PCP) may provide additional insight. CPT® (Current Procedural Terminology) is a registered trademark of the American Medical Association (AMA). CPT® five digit codes, nomenclature and other data are copyright 2017 American Medical Association. All Rights Reserved. No fee schedules, basic units, relative values or related listings are included in the CPT® book. AMA does not directly or indirectly practice medicine or dispense medical services. AMA assumes no liability for the data contained herein or not contained herein. © 2019 eviCore healthcare. All rights reserved. Spine Imaging Guidelines V1.0 Spine Imaging Guidelines Procedure Codes Associated with Spine Imaging 3 SP-1: General Guidelines 5 SP-2: Imaging Techniques 14 SP-3: Neck (Cervical Spine) Pain Without/With Neurological Features (Including Stenosis) and Trauma 22 SP-4: Upper Back (Thoracic Spine) Pain Without/With Neurological Features (Including Stenosis) and Trauma 26 SP-5: Low Back (Lumbar Spine) Pain/Coccydynia without Neurological Features 28 SP-6: Lower Extremity Pain with Neurological Features (Radiculopathy, Radiculitis, or Plexopathy and Neuropathy) With or Without Low Back (Lumbar Spine) Pain 32 SP-7: Myelopathy 36 SP-8: Lumbar Spine Spondylolysis/Spondylolisthesis 39 SP-9: Lumbar Spinal Stenosis 42 SP-10: Sacro-Iliac (SI) Joint Pain, Inflammatory Spondylitis/Sacroiliitis and Fibromyalgia 44 SP-11: Pathological Spinal Compression Fractures 47 SP-12: Spinal Pain in Cancer Patients 49 SP-13: Spinal Canal/Cord Disorders (e.g. -
Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs. -
(12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub
US 2010O221245A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0221245 A1 Kunin (43) Pub. Date: Sep. 2, 2010 (54) TOPICAL SKIN CARE COMPOSITION Publication Classification (51) Int. Cl. (76) Inventor: Audrey Kunin, Mission Hills, KS A 6LX 39/395 (2006.01) (US) A6II 3L/235 (2006.01) A638/16 (2006.01) Correspondence Address: (52) U.S. Cl. ......................... 424/133.1: 514/533: 514/12 HUSCH BLACKWELL SANDERS LLP (57) ABSTRACT 4801 Main Street, Suite 1000 - KANSAS CITY, MO 64112 (US) The present invention is directed to a topical skin care com position. The composition has the unique ability to treat acne without drying out the user's skin. In particular, the compo (21) Appl. No.: 12/395,251 sition includes a base, an antibacterial agent, at least one anti-inflammatory agent, and at least one antioxidant. The (22) Filed: Feb. 27, 2009 antibacterial agent may be benzoyl peroxide. US 2010/0221 245 A1 Sep. 2, 2010 TOPCAL SKIN CARE COMPOSITION stay of acne treatment since the 1950s. Skin irritation is the most common side effect of benzoyl peroxide and other anti BACKGROUND OF THE INVENTION biotic usage. Some treatments can be severe and can leave the 0001. The present invention generally relates to composi user's skin excessively dry. Excessive use of some acne prod tions and methods for producing topical skin care. Acne Vul ucts may cause redness, dryness of the face, and can actually garis, or acne, is a common skin disease that is prevalent in lead to more acne. Therefore, it would be beneficial to provide teenagers and young adults. -
Non-Steroidal Anti-Inflammatory Drugs Inhibit Bone Healing: a Review S
Review Article © Schattauer 2010 385 Non-steroidal anti-inflammatory drugs inhibit bone healing: A review S. Barry Washington State University, Department of Veterinary Clinical Sciences, Veterinary Teaching Hospital, Pullman, Wash- ington, USA crine and autocrine activity, have since Keywords stems from prostaglandin inhibition and is been shown to regulate constitutive and in- Non-steroidal anti-inflammatory drugs, likely multifactorial. In human medicine ducible functions throughout the body, in- NSAID, bone healing NSAID are known to prevent heterotopic ossi- cluding bone healing (5–9). The mech- fication, however the clinical importance of anism of NSAID inhibition to bone healing Summary their effects on bone healing remains contro- is unknown, but is likely multifactorial. Re- The ability of non-steroidal anti-inflammatory versial. Although a small handful of reports searchers have suggested that NSAID affect drugs (NSAID) to inhibit bone healing has suggest that NSAID suppress bone healing in normal bone healing in multiple ways, with been established in experimental animal dogs and horses, there is little published infor- emphasis often (but not exclusively) placed models using mice, rats, and rabbits. The mation to direct veterinary practice in do- on processes related to the inflammatory mechanism of action is largely unknown but mestic species. stage. Deciphering the mechanism of NSAID inhibition requires an understanding of Correspondence to: Vet Comp Orthop Traumatol 2010; 23: 385–392 Sabrina Barry, DVM doi:10.3415/VCOT-10-01-0017 fracture healing. Fracture healing presents Washington State University Received: January 31, 2010 an exquisitely orchestrated series of coor- Department of Veterinary Clinical Sciences Accepted: June 23, 2010 dinated molecular and cellular events. -
Latest Administration Hour Prior to Competition Max Dosage Per Pound of Body Weight Medication Trade Name Medication Generic Name
MEDICATION MEDICATION MAX DOSAGE PER POUND LATEST ADMINISTRATION HOUR ADMINISTRATION METHOD GENERIC NAME TRADE NAME OF BODY WEIGHT PRIOR TO COMPETITION (single dose per 24 hours unless specified otherwise) Dexamethasone Azium® 2.0 mg/100Lb >12 hours IV, IM (20 mg/1000Lb) or 0.5 mg/100Lb >6 hours IV (5.0 mg/1000Lb) or 1.0 mg/100LB >6 hours Oral (10 mg/1000Lb) Diclofenac Surpass® 5 inch ribbon, 1⁄2 inch thick, >12 hours Topical, 2 doses each day 12 hours apart one site Firocoxib Equioxx® 0.1 mg/kg >12 hours Oral (0.0455 mg/Lb) (45.5 mg/1000Lb) Phenylbutazone (“bute”) * Butazolidin® 2.0 mg/Lb >12 hours Oral, IV (2.0 grams/1000Lb) or 1.0 mg/Lb AM & PM feed Oral, 2 doses each day, 12 hours apart (1.0 grams/1000Lb) Flunixin meglumine * Banamine® 0.5 mg/Lb >12 hours Oral, IV (500 mg/1000Lb) Ketoprofen Ketofen® 1.0 mg/Lb >4 hours, but IV (1.0 gram/1000Lb) >6 hours is recommended Meclofenamic acid Arquel® 0.5 mg/Lb Oral, 2 doses each day, 12 hours apart (500 mg/1000Lb) Naproxen Naprosyn® 4.0 mg/Lb >12 hours Oral (4.0 grams/1000Lb) Eltenac Not yet approved Telzenac® 0.25 mg/Lb (250 mg/1000Lb) 12 hours IV Methocarbamol Robaxin® 5.0 mg/Lb >6 hours Oral, IV, 2 doses each day, 12 hours apart (5.0 grams/1000Lb) * Do not administer phenylbutazone and flunixin at the same time (Unless used according to The maximum treatment time for any of the above permitted medication is five days, with the Section 8). -
Simultaneous Determination of Residues of Non-Steroidal Anti-Inflammatory Drugs and Glucocorticosteroids in Animal Muscle By
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector Food Anal. Methods (2016) 9:1837–1848 DOI 10.1007/s12161-015-0352-y Simultaneous Determination of Residues of Non-Steroidal Anti-Inflammatory Drugs and Glucocorticosteroids in Animal Muscle by Liquid Chromatography-Tandem Mass Spectrometry Piotr Jedziniak1 & Małgorzata Olejnik1 & Konrad Pietruk1 & Edyta Protasiuk1 & Teresa Szprengier-Juszkiewicz1 & Jan Żmudzki1 Received: 11 February 2015 /Accepted: 4 November 2015 /Published online: 21 November 2015 # The Author(s) 2015. This article is published with open access at Springerlink.com Abstract A method for the determination of a wide range Introduction residues of anti-inflammatory drugs (16 acidic non-steroidal anti-inflammatory drugs and four metamizole metabolites and Non-steroidal anti-inflammatory drugs (NSAIDs) and five corticosteroids) has been was developed. In the first step glucocorticosteroids (GCs) are widely used in veterinary medi- of sample preparation, acetate buffer was added to minced cine as well as in treatment of diseases in food-producing ani- muscle samples and 15-min ultrasound-assisted enzymatic mals. Despite its effectiveness, the important drawback of phar- hydrolysis was performed. Next, the samples were extracted macotherapy is drug residues in animal tissues. It became an twice with acetonitrile, freezed and analysed. The analytes important issue in the food safety. Potential toxicity of medicinal were separated on a C18 column with a 25-min gradient of veterinary products has to be evaluated before the drug registra- methanol/acetonitrile (8:2) and 0.05 M ammonium formate at tion. When necessary, maximum residue limits (MRLs) in food pH 5.0 and determined by liquid chromatography-tandem are established. -
Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11. -
Ige-Mediated Hypersensitivity to Lysine Clonixinate
67 Practitioner's Corner IgE-Mediated Hypersensitivity to Lysine Clonixinate Villalón García AL, Pérez Pimiento A, López San Martín MG, Iglesias Cadarso A Allergy Department, University Hospital Puerta de Hierro, Madrid, Spain J Investig Allergol Clin Immunol 2021; Vol. 31(1): 67-68 doi: 10.18176/jiaci.0613 Key words: Lysine clonixinate. Drug allergy. Anti-inflammatory analgesics. Urticaria. IgE-mediated hypersensitivity. Palabras clave: Clonixinato de lisina. Alergia a medicamentos. Analgésicos antiinflamatorios. Urticaria. Hipersensibilidad mediada por IgE. Lysine clonixinate belongs to the nicotinic acid family, a family of nonsteroidal anti-inflammatory drugs (NSAIDs), which are in turn a class of antiprostaglandin drugs. At therapeutic doses, it acts mainly by inhibiting cyclooxygenase 2 (COX-2), whereas at lower doses, it inhibits cyclooxygenase 1 (COX-1). It is indicated as an analgesic and anti-inflammatory drug in patients with acute or chronic pain and has proven effective in various algic syndromes such as renal colic, nerve compression, muscular pain, and odontalgia [1]. It is generally administered orally, Figure. Skin prick test. although it is also effective and well tolerated intravenously for the treatment of severe migraine attacks [1-3]. Little is known about cross-reactivity between nicotinic acid family anti-inflammatory drugs (lysine clonixinate, morniflumate, to NSAIDs. Oral challenge with lysine clonixinate was not isonixin, and niflumic acid) in acute allergic reactions. Most performed. Skin prick testing with morniflumate, isonixin, are used as a useful alternative in patients with NSAID niflumic acid, and acetylsalicylic acid dissolved in saline was hypersensitivity [4]. Numerous studies compare the efficacy negative. Oral challenge with acetylsalicylic acid 1 g was well and tolerance profile of oral lysine clonixinate with that of tolerated.